Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity.
Reiners KS, Topolar D, Henke A, Simhadri VR, Kessler J, Sauer M, Bessler M, Hansen HP, Tawadros S, Herling M, Krönke M, Hallek M, Pogge von Strandmann E. Reiners KS, et al. Among authors: pogge von strandmann e. Blood. 2013 May 2;121(18):3658-65. doi: 10.1182/blood-2013-01-476606. Epub 2013 Mar 18. Blood. 2013. PMID: 23509156 Free PMC article.
Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells.
Pogge von Strandmann E, Simhadri VR, von Tresckow B, Sasse S, Reiners KS, Hansen HP, Rothe A, Böll B, Simhadri VL, Borchmann P, McKinnon PJ, Hallek M, Engert A. Pogge von Strandmann E, et al. Among authors: von tresckow b. Immunity. 2007 Dec;27(6):965-74. doi: 10.1016/j.immuni.2007.10.010. Epub 2007 Dec 6. Immunity. 2007. PMID: 18055229 Free article.
Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC.
Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, Le Chevalier T, Livartoski A, Barlesi F, Laplanche A, Ploix S, Vimond N, Peguillet I, Théry C, Lacroix L, Zoernig I, Dhodapkar K, Dhodapkar M, Viaud S, Soria JC, Reiners KS, Pogge von Strandmann E, Vély F, Rusakiewicz S, Eggermont A, Pitt JM, Zitvogel L, Chaput N. Besse B, et al. Among authors: pogge von strandmann e. Oncoimmunology. 2015 Aug 12;5(4):e1071008. doi: 10.1080/2162402X.2015.1071008. eCollection 2016 Apr. Oncoimmunology. 2015. PMID: 27141373 Free PMC article.
Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia.
Vyas M, Schneider AC, Shatnyeva O, Reiners KS, Tawadros S, Kloess S, Köhl U, Hallek M, Hansen HP, Pogge von Strandmann E. Vyas M, et al. Among authors: pogge von strandmann e. Oncoimmunology. 2016 Jul 15;5(9):e1211220. doi: 10.1080/2162402X.2016.1211220. eCollection 2016. Oncoimmunology. 2016. PMID: 27757305 Free PMC article.
RIG-I activation induces the release of extracellular vesicles with antitumor activity.
Daßler-Plenker J, Reiners KS, van den Boorn JG, Hansen HP, Putschli B, Barnert S, Schuberth-Wagner C, Schubert R, Tüting T, Hallek M, Schlee M, Hartmann G, Pogge von Strandmann E, Coch C. Daßler-Plenker J, et al. Among authors: pogge von strandmann e. Oncoimmunology. 2016 Aug 19;5(10):e1219827. doi: 10.1080/2162402X.2016.1219827. eCollection 2016. Oncoimmunology. 2016. PMID: 27853642 Free PMC article.
CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro.
Hansen HP, Trad A, Dams M, Zigrino P, Moss M, Tator M, Schön G, Grenzi PC, Bachurski D, Aquino B, Dürkop H, Reiners KS, von Bergwelt-Baildon M, Hallek M, Grötzinger J, Engert A, Paes Leme AF, Pogge von Strandmann E. Hansen HP, et al. Among authors: von bergwelt baildon m, pogge von strandmann e. Oncotarget. 2016 May 24;7(21):30523-35. doi: 10.18632/oncotarget.8864. Oncotarget. 2016. PMID: 27105521 Free PMC article.
55 results